| Drug Type Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals | 
| Synonyms- | 
| Target | 
| Action inhibitors | 
| Mechanism MMP14 inhibitors(Matrix metalloproteinase 14 inhibitors), MT1 inhibitors(ALG1 chitobiosyldiphosphodolichol beta-mannosyltransferase inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 

| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Glioma | Preclinical | China  | 25 Aug 2025 | |
| Pancreatic Cancer | Preclinical | China  | 25 Aug 2025 | 





